Immunosuppressive agents for dermatological indications in the ongoing COVID 19 pandemic: rationalizing use and clinical applicability.

Immunosuppressive agents for dermatological indications in the ongoing COVID 19 pandemic: rationalizing use and clinical applicability.

Publication date: May 21, 2020

The ongoing COVID 19 epidemic has brought to the fore many concerns related to use of immunosuppressive agents (ISAs) in dermatology. While it is unclear whether the patients on ISAs for skin conditions are more prone to develop COVID 19, and what impact the ISA may have on the clinical outcome if a patient does get infected, rationalizations based on the specific immune effects of each drug, and existing literature on incidence of various infections with each, are possible. In this review, we provide the readers with practically useful insights into these aspects, related to the conventional ISAs, and briefly mention the clinical outcome data available on related scenarios from other patient groups so far. In the end, we have attempted to provide some clinically useful points regarding practical use of each dermatologically relevant conventional ISA in the current scenario. This article is protected by copyright. All rights reserved.

Concepts Keywords
Dermatological Incidence infections
Dermatology Medical specialties
Epidemic Medicine
Immunosuppressive Agents Clinical medicine
Incidence Immunosuppressants
ISA RTT
Pandemic Autoimmune diseases
Mycophenolic acid
Phenols
Phthalides
Immunosuppressive drug
Azathioprine

Semantics

Type Source Name
disease MESH infections
drug DRUGBANK Azathioprine
drug DRUGBANK Ciclosporin
drug DRUGBANK Cyclophosphamide
drug DRUGBANK Methotrexate
drug DRUGBANK Mycophenolic acid

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *